2021年

1. Hiratsuka Y, Suh SY, Maeda I, Morita T, Mori M, Ito S, Nishi T, Hisanaga T, Iriyama T, Kaneishi K, Ikari T, Tagami K, Inoue A. Factors influencing spiritual well-being in terminally ill cancer inpatients in Japan. Supprt Care Cancer 2021; 29: 2795-802.
2. Kawashima K, Harada T, Fujita Y, Nakagawa T, Watanabe K, Morikawa N, Takamura K, Kanazawa K, Kuda T, Usui K, Sekine A, Inoue A, Sugawara S. Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan Lung Cancer Study Group 1302. Int J Clin Oncol 2021; 26: 515-22.
3. Watanabe K, Toi Y, Nakamura A, Chiba R, Akiyama M, Sakakibara-Konishi J, Tanaka H, Yoshimura N, Miyauchi E, Nakagawa T, Igusa R, Minemura H, Mori Y, Fujimoto K, Matsushita H, Takahashi F, Fukuhara T, Inoue A, Sugawara S, Maemondo M. Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001. Transl Lung Cancer Res 2021; 10: 712-22. 2021; 10: 712-22.
4. Miyagi T, Miyata S, Tagami K, Hiratsuka Y, Sato M, Takeda I, Kohata K, Satake N, Shimokawa H, Inoue A. Prognostic model for patients with advanced cancer using a combination of routine blood test values. Support Care Cancer 2021 Jan 14. [online ahead of print]
5. Hiratsuka Y, Oishi T, Miyashita M, Morita T, Mack JW, Takahashi M, Shirota H, Otsuka K, Ishioka C, Inoue A. Patients’ understanding of communication about palliative care and health condition in Japanese patients with unresectable or recurrent cancer: A cross-sectional survey. Ann Palliati Med 2021; 10: 2650-61.
6. Ikari T, Hiratsuka Y, Yamaguchi T, Maeda I, Mori M, Uneno Y, Taniyama T, Matsuda Y, Oya K, Tagami K, Inoue A. 3-Day Surprise Question” to predict prognosis of advanced cancer patients with impending death: multicenter prospective observational study. Cancer Med 2021; 10: 1018-26.
7. Hiramoto S, Taniyama T, Hori T, Kikuchi A, Yoshioka A, Inoue A. Effect of molecular targeting agents and immune-checkpoint inhibitors use near the end of life in patients with advanced cancer who are near the end of life. Palliat Support Care 2021 Mar 17:1-6. [online ahead of print]
8. Zenda S, Uchitomi Y, Morita T, Yamaguchi T, Inoue A. Establishment of a Research Policy for Supportive and Palliative Care in Japan. Jpn J Clin Oncol 2021; 51: 538-43.
9. Hiratsuka Y, Suh SY, Kim SH, Cheng SY, Yoon SJ, Koh SJ, Park SA, Seo JY, Kwon JH, Park J, Park Y, Hwang SQ, Lee ES, Ahn HY, Hui D, Chen PJ, Yamaguchi T, Morita T, Tsuneto S, Mori M, Inoue A. Factors related to spiritual well-being in the last days of life in three East Asian countries: an international multicenter prospective cohort study. Palliat Med 2021 [online ahead of print]
10. Isseki Maeda, Eriko Satomi, Daisuke Kiuchi, Kaoru Nishijima , Yoshinobu Matsuda , Akihiro Tokoro , Keita Tagami , Yoshihisa Matsumoto , Akemi Naito , Tatsuya Morita , Satoru Iwase , Phase-R N/V Study Group Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study Support Care Cancer . 2021 Mar 20. ［Epub ahead of print］
11. Isseki Maeda , Shinichiro Inoue , Keiichi Uemura , Hitoshi Tanimukai , Yutaka Hatano , Naosuke Yokomichi , Koji Amano , Keita Tagami , Kazuhiro Yoshiuchi , Asao Ogawa , Satoru Iwase , Low-Dose Trazodone for Delirium in Patients with Cancer Who Received Specialist Palliative Care: A Multicenter Prospective Study J Palliat Med . 2021 Jun;24(6):914-918.
12. 佐藤 麻美子, 田上 恵太, 田上 佑輔, 青山 真帆, 井上 彰. 緩和ケアの専門家が不在な地域における訪問看護師の緩和ケアの困難感、自信・意欲、実践のアンケート調査、および緩和ケアアウトリーチ介入点の検討
    Palliative Care Research (1880-5302) 2021;16巻1号 :79-84.
13. 吉田 詩織, 佐藤 冨美子, 田上 恵太, 霜山 真, 高橋 信. 遠隔看護によるがん疼痛モニタリングシステムのパイロットユーザビリティ評価
    Palliative Care Research (1880-5302) 2021; 16巻1号 :99-108.

2020年

1. Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol 2020; 38: 115-23.
2. Higashibata T, Tagami K, Miura T, Okizaki A, Watanabe YS, Matsumoto Y, Morita T, Kinoshita H. Usefulness of painDETECT and S-LANSS in identifying the neuropathic component of mixed pain among patients with tumor-related cancer pain. Support Care Cancer. 2020 Jan;28(1):279-285.
3. Tagami K, Kawaguchi T, Miura T, Yamaguchi T, Matsumoto Y, Sumazaki-Watanabe Y, Uehara Y, Okizaki A, Inoue A, Morita T, Kinoshita H. The association between health-related quality of life and achievement of personalized symptom goal. Support Care Cancer 2020; 28: 4737-43.
4. Sekine I, Shintani Y, Shukuya T, Takayama K, Inoue Aｃｃｃ, Okamoto I, Kiura K, Takahashi K, Akita H, Takiguchi Y, Miyaoka E, Okumura M, Yoshino I. Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. Cancer Sci 2020; 111: 1685-91.
5. Hiratsuka Y, Yamaguchi T, Maeda I, Morita T, Mori M, Yokomichi N, Hiramoto S, Matsuda Y, Kohara H, Suzuki K, Tagami K, Yamaguchi T, Inoue A. The Functional Palliative Prognostic Index: a scoring system for functional prognostication of patients with advanced cancer. Support Care Cancer. 2020; 28: 6067-74.
6. Hiratsuka Y, Aoyama M, Kaneta T, Masukawa K, Tagami K, Miyashita M, Inoue A. Impressions of Interfaith Chaplain's Activities among Patients in a Palliative Care Unit: A Semi-Structured Interview-Based Qualitative Study. Tohoku J Exp Med 2020; 251: 91-6.
7. Igawa S, Naoki K, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Takiguchi Y, Miyaoka E, Okumura M, Yoshino I. Survival and Prognostic Factors in Elderly Patients Receiving Second-line Chemotherapy for Relapsed Small-Cell Lung Cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. Lung Cancer 2020. 146:160-164.
8. Kobayashi K, Soejima K, Fukunaga K, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Takiguchi Y, Miyaoka E, Okumura M, Yoshino I. Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registory Database. Lung Cancer 2020; 146: 236-43.
9. Tagami K, Matsuoka H, Ariyoshi K, Oyamada S, Hiratsuka Y, Kizawa Y, Koyama A, Inoue A. The current clinical use of adjuvant analgesics for refractory cancer pain in Japan: A nationwide cross-sectional survey. Jpn J Clin Oncol 2020;　50:　1434-41.
10. Shih JY, Inoue A, Cheng R, Varea R, Kim SW. Does pemetrexed work on targetable, non-squamous, non-small-cell lung cancer? A Narrative Review. Cancers (Basel) 2020; 12: 2658.
11. Yatabe Y, Tsunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H. Multiplex Gene-panel Testing for Lung Cancer Patients. Pathol Int 2020; 70: 921-31.
12. Tagami K, Yoshizumi M, Inoue A, Matoba M. Effectiveness of Gabapentinoids for Cancer-related Rectal and Vesical Tenesmus: Report of Four Cases. Indian J Palliat Care 2020; 26: 381-4.

2019年

1. Inoue A, Yamaguchi T, Tanaka K, Sakashita A, Aoe K, Seki N, Hagiwara K. Benefits of a Nationwide Palliative Care Education Program on Lung Cancer Physicians. Intern Med 2019.
2. Mori M, Fujimori M, van Vliet LM, Yamaguchi T, Shimizu C, Kinoshita T, Morishita-Kawahara M, Inoue A, Inoguchi H, Matsuoka Y, Bruera E, Morita T, Uchitomi Y.Explicit prognostic disclosure to Asian women with breast cancer: A randomized, scripted video-vignette study (J-SUPPORT1601). Cancer 2019; 125: 3320-339.
3. Kikuchi K, Nozawa K, Inoue A, et al. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. J Dermatol 2019; 46: 18-25.
4. Matsuoka H, Tagami K, Ariyoshi K, Oyamada S, Kizawa Y, Inoue A, Koyama A. Attitude of Japanese Palliative Care Specialists Towards Adjuvant Analgesics Cancer -related Neuropathic Pain Non-responsive or Intolerant to Opioid Therapy: A Nationwide Cross-Sectional Survey. Jpn J Clin Oncol 2019; 49: 486-90.
5. Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T. Japanese Subgroup Analysis of a Phase III Study of S-1 versus Docetaxel in Non-Small Cell Lung Cancer Patients After Platinum-Based Treatment: EAST-LC. Int J Clin Oncol 2019; 24: 485-93.
6. Tsukita Y, Fujino N, Miyauchi E, Saito R, Fujishima F, Itakura K, Kyogoku Y, Okutomo K, Yamada M, Okazaki T, Sugiura H, Inoue A, Okada Y, Ichinose M. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas. Molecular Cancer 2019; 18: 24.
7. Hiratsuka Y, Tagami K, Inoue A. Refractory chest pain induced by implantable cardioverter-defibrillator (ICD) in a patient with advanced cancer: What is the best timing for deactivation of an ICD? J Palliat Med 2019; 22: (7): 745-6.
8. Hiramoto S, Tamaki T, Nagashima K, Hori T, Kikuchi A, Yoshioka A, Inoue A. Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer. Int J Clin Oncol 2019; 24: 454-9.
9. Tsukita Y, Inoue A, Sugawara S, Kuyama S, Nakagawa T, Harada D, Tanaka H, Watanabe K, Mori Y, Harada T, Hino T, Fujii M, Ichinose M. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan Lung Cancer Study Group Trial 1203. Lung Cancer. 2019; 139:89-93.
10. Miura T, Matsumoto Y, Kawaguchi T, Masuda Y, Okizaki A, Koga H, Tagami K, Watanabe YS, Uehara Y, Yamaguchi T, Morita T. Low Phase Angle Is Correlated With Worse General Condition in Patients with Advanced Cancer. Nutr Cancer. 2019;71(1):83-88.
11. Okuyama T, Yoshiuchi K, Ogawa A, Iwase S, Yokomichi N, Sakashita A, Tagami K, Uemura K, Nakahara R, Akechi T; Phase‐R Delirium Study Group. Current Pharmacotherapy Does Not Improve Severity of Hypoactive Delirium in Patients with Advanced Cancer: Pharmacological Audit Study of Safety and Efficacy in Real World (Phase-R). Oncologist. 2019 Jul;24(7):e574-e582.

2018年

1. Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura Katsuyuki, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K. Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations. Cancer Sci 2018; 109:2852-62.
2. Hosomi Y, Tanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H. Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert Opin Pharmacother. 2018; 19:1049-56.
3. Oishi T, Sato K, Morita T, Mack JW, Shimodaira H, Takahashi M, Takahashi S, Inoue A, Murakawa Y, Kawahara M, Ishioka C, Miyashita M. Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey. Jpn J Clin Oncol. 2018; 48: 913-9.
4. Kogure Y, Saka H, Takiguchi Y, Atagi S, Kurata T, Ebi N, Inoue A, et al. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. Clin Lung Cancer. 2018 Sep;19(5):e711-e715.
5. Tagami K, Okizaki A, Miura T, Watanabe YS, Matsumoto Y, Morita T, Fujimori M, Kinoshita H. Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain. J Palliat Med. 2018 Nov;21(11):1636-1640.
6. Watanabe YS, Miura T, Okizaki A, Tagami K, Matsumoto Y, Fujimori M, Morita T, Kinoshita H. Comparison of Indicators for Achievement of Pain Control With a Personalized Pain Goal in a Comprehensive Cancer Center. J Pain Symptom Manage. 2018 Apr;55(4):1159-1164.
7. Isamu Okamoto,j Satoshi Morita, Naoki Tashiro, Fumio Imamura, Akira Inoue, Takashi Seto, Nobuyuki Yamamoto, Yuichiro Ohe, Kazuhiko Nakagawa, Masahiro Fukuoka. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohortLung Cancer 2018; 117: 14-19.
8. Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T.Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. ESMO Open 2018; 3: e000313.
9. Yoshihito Kogure, M.D.; Hideo Saka, M.D.; Yuichi Takiguchi, M.D.; Shinji Atagi, M.D.; Takayasu Kurata, M.D.; Noriyuki Ebi, M.D.; Akira Inoue, M.D.; Kaoru Kubota, M.D.; Mitsuhiro Takenoyama, M.D.; Takashi Seto, M.D.; Akiko Kada, MPH.; Takeharu Yamanaka; Masahiko Ando, M.D.; Nobuyuki Yamamoto, M.D.; Akihiko Gemma, M.D.; Yukito Ichinose, M.D. A Randomized Phase III Study Comparing Carboplatin plus Nab-Paclitaxel versus Docetaxel for Elderly Patients with Squamous Cell Lung Cancer: Study Protocol. Clin Lung Cancer 2018; S1525-7304: 30110-4.
10. Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K. ASP8273 tolerability and antitumor activity in TKI-naive Japanese patients with EGFR mutation-positive non-small cell lung cancer. Cancer Sci 2018 (epub ahead of print)
11. Nihei S, Sato J, Harada T, Kuyama S, Suzuki T, Waga N, Saito Y, Kisara S, Yokota A, Okada K, Tsuchiya M, Terui K, Tadokoro Y, Chiba T, Kudo K, Oizumi S, Inoue A, Morikawa N.　Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab. Cancer Chemother Pharmacol. 2018 Jun;81(6):1051-1059.
12. Uchida T, Satake N, Nakaho T, Inoue A, Saito H. Bereavement risk assessment of family caregivers of patients with cancer: Japanese version of the Bereavement Risk Assessment Tool. Palliat Support Care. 2018 Nov 14:1-5.
13. 井上彰：より良く生きるための緩和ケア．宮城県公衆衛生協会　公衆衛生情報みやぎ2018, 478:4-5.
14. 平塚裕介, 佐藤麻美子, 小野寺克洋, 佐藤勝智, 木幡桂, 田上恵太, 宮城妙子, 佐竹宣明, 井上彰. 悪性消化管閉塞患者におけるデキサメタゾンによる経口摂取量改善効果の後方視的検討. Palliative Care Research, 2018, 13.3: 229-233.

2017年

1. Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Kuriki H, Shimada T, Tanaka T, Takeuchi K, Nishio M: Three-year Follow-up of an Alectinib Phase 1/2 study in ALK-positive Non-Small-Cell Lung Cancer: AF-001JP. J Clin Oncol 2017; 35: 1515-21.
2. Miura S, Maemondo M, Iwashima A, Harada T, Sugawara S, Kobayashi K, Inoue A, Nakagawa T, Takiguchi Y, Watanabe H, Ishida T, Terada M, Kagamu H, Gemma A, Yoshizawa H： A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016). Investig New Drug 2017; 35: 227-34.
3. Tode N, Kikuchi T, Sakakibara T, Hirano T, Inoue A, Ohkouchi S, Tamada T, Okazaki T, Koarai A, Sugiura H, Niihori T, Aoki Y, Nakayama K, Matsumoto K, Matsubara Y, Yamamoto M, Watanabe A, Nukiwa T, Ichinose M: Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. Cancer Sci 2017; 108: 1263-70.
4. Miyauchi E, Ichinose M, Inoue A: Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease. J Thorac Oncol 2017; 12: e59-e61.
5. Miyauchi E, Inoue A, Usui K, et al.: Phase II study of modified carboplatin plus weekly nab-paclitaxel in elderly patients with non-small cell lung cancer: North Japan Lung Cancer Study Group Trial 1301. Oncologist 2017; 6: 640-e59.
6. Tominaga M, Okamoto M, Kawayama T, Matsuoka M, Kaieda S,MD, Sakazaki Y, Kinoshita T, Mori D, Inoue A, Hoshino T: Overexpression of IL-38 protein in anticancer drug-induced lung injury and acute exacerbation of idiopathic pulmonary fibrosis. Respirat Investig 2017: 55; 293-9.
7. Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H: Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open 2017; 2: e000214.
8. Kosugi K, Tagami K, Tanimoto T: Trial of Pregabalin for Acute and Chronic Sciatica. N Engl J Med. 2017 Jun 15;376(24):2396.
9. Kako J, Kobayashi M, Kanno Y, Tagami K: Intranasal Vinegar as an Effective Treatment for Persistent Hiccups in a Patient With Advanced Cancer Undergoing Palliative Care. J Pain Symptom Manage. 2017 Aug;54(2):e2-e4.
10. Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC. Gefitinib or erlotinib versus chemotherapy for EGFR mutation-positive lung cancer: individual-patient-data meta-analysis of overall survival. J Natl Cancer Inst 2017; 109: djw279.
11. Yoh K, Goto Y, Naito Y, Kishi K, Mori K, Hotta K, Hosomi Y, Yamada K, Tanai C, Tomizawa Y, Inoue A, Hasegawa Y, Nishio M, Ohashi Y, Kunitoh H. Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting. Anticancer Res 2017; 37: 1507-1513.
12. Takahashi K, Proshin S, Yamaguchi K,Yamashita, R. Katakura, K. Yamamoto, H. Shima, M. Hosono, Taeko Miyagi: Sialidase NEU3 defines invasive potential of human glioblastoma cells by regulating calpain-mediated proteolysis of focal adhesion proteins. BBA General Subjects. 2017; 1861: 2778-88.

2016年

1. Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, Nakagawa K, Yamamoto N, Muto S, Fukuoka M : Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: A Retrospective Analysis for 1,660 Japanese patients. Jpn J Clin Oncol. 2016; 45: 462-7.
2. Takeuchi K, Togashi Y, Kamihira Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T : Prospective and clinical validation of ALK immunohistochemistry: Results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol. 2016; 27: 185-92.
3. Shiono M, Huang K, Downey R, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk A, Inoue A, Halmos B, Acharyya S : The association between metastasis and cachexia in lung cancer. Cancer Med. 2016; 5: 2641-8.
4. Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M, Kagamu H, Hagiwara K, Kobayashi K : A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung Cancer. 2016; 99: 131-6.
5. Scagliotti G, Nishio M, Satouchi M, Valmadre G, Niho S, Galetta D, Cortinovis D, Benedetti F, Yoshihara E, Makris L, Inoue A, Kubota K : Phase 2 randomized study of TAS-102 versus topotecan oramrubicin in patients requiring second-line chemotherapy for smallcell lung cancer refractory or sensitive to frontline platinum-basedchemotherapy. Lung Cancer. 2016; 100: 20-23.
6. Nakajima N, Abe Y : Concurrent specialized palliative care upon initiation of first-line chemotherapy for cancer progression:Is it early enough? Am J Hosp Palliat Med. 2016; 33: 340-345.
7. Nakajima N: Characteristics of oral problems and effects of oral care in terminally ill patients in cancer. Am J Hosp Palliat Med. 2016; 22 Feb: [Epub ahead of print]
8. Higashiguchi T, Ikegaki J, Sobue K, Tamura Y, Nakajima N, Futamura A, Miyashita M, Mori N, Inui A, Ohta K, Hosokawa T : Guidelines for parenteral fluid management for terminal cancer patients. Jpn J Clin Oncol. 2016; 12 Aug: [Epub ahead of print]
9. Hamano J, Yamaguchi T, Maeda I, Suga A, Hisanaga T, Ishihara T, Iwashita T, Kaneishi K, Kawagoe S, Kuriyama T, Maeda T, Mori I, Nakajima N, Nishi T, Sakurai H, Shimoyama S, Shinjo T, Shirayama H, Yamada T, Morita T: Multicenter cohort study on the survival time of cancer patients dying at home or in a hospital. Cancer. 2016; 122: 1453-1460.
10. Miyagi T: Glycosignals in Cancer : Differential roles of mammalian sialidases in cancers. （Eds by Furukawa K, and Fukuda M), Springer 2016 ; 35-53.
11. 中島信久: がん終末期の口腔ケア－口腔乾燥の現状と全人的苦痛の視点からみた問題点－．日本口腔ケア学会雑誌2016; 11: 19-23.

2015年

1. Watanabe S, Inoue A, Nukiwa T, Kobayashi K. Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion. Anticancer Res 2015; 35: 6957-61.
2. Ishimoto O, Sugawara S, Inoue A, Maemondo M, Nukiwa T. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study. Respir Investig 2015; 53: 156-60.
3. Inoue A, Sugawara S, Maemondo M, et al. Randomized Phase II Trial Comparing Amrubicin with Re-challenge of Platinum Doublet in Patients with Sensitive-Relapsed Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0702. Lung Cancer 2015; 89: 61-5.
4. Nakajima N, Kusumoto K, Onishi H, Ishida M. Does the Approach of Disclosing More Detailed Information of Cancer for the Terminally Ill Patients Improve the Quality of Communication Involving Patients, Families, and Medical Professionals?　Am J Hosp Palliat Care 2015; 32: 776-82.
5. Baba M, Maeda I, Morita T, Hisanaga T, Ishihara T, Iwashita T, Kaneishi K, Kawagoe S, Kuriyama T, Maeda T, Mori I, Nakajima N, Nishi T, Sakurai H, Shimoyama S, Shinjo T, Shirayama H, Yamada T, Ono S, Ozawa T, Yamamoto R, Tsuneto S.　Independent validation of the modified prognosis palliative care study predictor models in three palliative care settings.　J Pain Symptom Manage 2015; 49: 853-60.
6. Miura T, Matsumoto Y, Hama T, Amano K, Tei Y, Kikuchi A, Suga A, Hisanaga T, Ishihara T, Abe M, Kaneishi K, Kawagoe S, Kuriyama T, Maeda T, Mori I, Nakajima N, Nishi T, Sakurai H, Morita T, Kinoshita H. Glasgow prognostic score predicts prognosis for cancer patients in palliative settings: a subanalysis of the Japan-prognostic assessment tools validation (J-ProVal) study. Support Care Cancer 2015; 23: 3149-56.
7. Takahashi K, Hosono M, Sato I, Hata K, Wada T, Yamaguchi K, Nitta K, Shima H, Miyagi T. Sialidase NEU3 contributes neoplastic potential on colon cancer cells as a key modulator of gangliosides by regulating Wnt signaling. Int J Cancer 2015; 137:1560-73.
8. Shiozaki K,　Takahashi K, Hosono M, Yamaguchi K, Hata H, Shiozaki M, Bassi R, Prinetti A, Sonnino S, Nitta K, Miyagi T. Phosphatidic acid-mediated activation and translocation to the cell surface of sialidase NEU3, promoting signaling for cell migration. FASEB J 2015; 29: 2099-111.
9. Morikawa N, Minegishi Y, Inoue A, Maemondo M, Kobayashi K, Sugawara S, Harada M, Hagiwara K, Okinaga S, Oizumi S, Nukiwa T, Gemma A; North-East Japan Study Group. First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. Expert Opin Pharmacother 2015; 16: 465-72.
10. Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa TRandomized Phase II Study of Concurrent Versus Sequential Alternating Gefitinib and Chemotherapy in Previously Untreated Non-small Cell Lung Cancer with Sensitive EGFR Mutations: NEJ005/TCOG0902. Ann Oncol 2015; 26: 888-94.
11. Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. J Clin Oncol 2015;33:1958-65
12. Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation. Lung Cancer 2015; 88: 181-6.
13. Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T; North-East Japan Study Group. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation positive advanced non-small cell lung cancer - data from a randomized phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002). Jpn J Clin Oncol 2015; 45: 670-6.
14. Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S; Tokyo Cooperative Oncology Group. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 2015; 26: 1401-8.
15. Dempke WC, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? Anticancer Res 2015; 35: 5797-806.
16. Nakajima N, Kusumoto K, Onishi H, Ishida M: Does the approach of disclosing more detailed information of cancer for the terminally ill patients improve the quality of communication involving patients, families, and medical professionals? Am J Hosp Palliat Care. 2015; Nov32(7): 776-782.

2014年

1. Nakajima N, Satake N, Nakaho T. Indications and practice of artificial hydration for terminally ill cancer patients. Curr Opin Support Palliat Care 2014; 8: 358-63.
2. Nakajima N, Takahashi Y, Ishitani K. The volume of hydration in terminally ill cancer patients with hydration-related symptoms: a prospective study. J Palliat Med 2014; 17: 1037-41.

2013年

1. Nakajima N, Hata Y, Onishi H, Ishida M　The Evaluation of the Relationship Between the Level of Disclosure of Cancer in Terminally Ill Patients With Cancer and the Quality of Terminal Care in These Patients and Their Families Using the Support Team Assessment Schedule.　American Journal of Hospice and Palliative Medicine　 30:370-376,2013
2. Nakajima N, Hata Y, Kusumoto K. A clinical study on the influence of hydration volume on the signs of terminally ill cancer patients with abdominal malignancies. J Palliat Med 2013; 16: 185-9.

2012年

1. Yamaguchi T, Morita T, Shinjo T, Inoue S, Takigawa C, Aruga E, Tani K, Hara T, Tamura Y, Suga A, Adachi S, Katayama H, Osaka I, Saito Y, Nakajima N, Higashiguti T, Hayashi T, Okabe T, Kohara H, Tamaki T, Chinone Y, Aragane H, Kanai Y, Tokura N, Yamaguchi T, Asada T, Uchitomi Y　Effect of Parenteral Hydration Therapy Based on the Japanese National Clinical Guideline on Quality of Life, Discomfort, and Symptom Intensity in patients with Advanced Cancer 　Journal of Pain and Symptom Management　43:1001-1012,2012

2008年

1. Tei Y, Morita T, Nakaho T, Takigawa C, Higuchi A, Suga A, Tajima T, Ikenaga M, Higuchi H, Shimoyama N, Fujimoto M. Treatment efficacy of neural blockade in specialized palliative care services in Japan: a multicenter audit survey. J Pain Symptom Manage. 2008 Nov;36(5):461-7.

2007年

1. Kikuchi N, Ohmori K, Kuriyama S, Shimada A, Nakaho T, Yamamuro M, Tsuji I. Survival prediction of patients with advanced cancer: the predictive accuracy of the model based on biological markers. J Pain Symptom Manage. 2007 Dec;34(6):600-6.